At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 13, 2026 at 07:00 ET
Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial, showing SPY001 achieved a statistically significant 9.2-point reduction in RHI score (p<0.0001) with strong secondary outcomes and a favorable safety profile. Enrollment has closed for Part A and moved to Part B, which includes monotherapy and combination cohorts, with data readouts expected through 2026–2027.
- SPY001 met primary endpoint with 9.2-point reduction in RHI score (p<0.0001) at Week 12 in Phase 2 SKYLINE trial Part A.
- Secondary endpoints: 40% clinical remission rate and 51% endoscopic improvement rate.
- SPY001 was well tolerated with no drug-related serious adverse events; most common AE was back pain (n=2).
- Part B of the SKYLINE trial is now enrolling, including combination cohorts with SPY002 and SPY003.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access